{"id":"W2752175334","doi":"10.1007/s12282-017-0798-4","title":"Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study","year":2017,"lang":"en","type":"article","venue":"Breast Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Eisai Canada; Japan Society of Clinical Oncology","keywords":"Capecitabine; Eribulin; Medicine; Metastatic breast cancer; Dosing; Internal medicine; Pharmacokinetics; Breast cancer; Neutropenia; Taxane; Anthracycline; Oncology; Gastroenterology; Toxicity; Pharmacology; Cancer; Urology; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002353894,0.0003310779,0.0008547739,0.0001346376,0.0003751947,0.00004876244,0.0001961696,0.00005014931,0.001694042],"category_scores_gemma":[0.00001558901,0.0002721863,0.00009990136,0.0001166453,0.0001414514,0.0001704618,0.0000991527,0.000153342,0.000003084869],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002466804,"about_ca_system_score_gemma":0.0003185553,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01176705,"about_ca_topic_score_gemma":0.006424231,"domain_scores_codex":[0.9982547,0.00006021802,0.0004382946,0.0005387602,0.0002894003,0.0004186213],"domain_scores_gemma":[0.998521,0.0000783802,0.0004023219,0.0005065984,0.0002547664,0.0002369495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.015829,0.02720553,0.7123982,0.0005424736,0.004290263,0.0002275403,0.006328704,0.00002596758,0.009306124,0.00001657395,0.004759219,0.2190704],"study_design_scores_gemma":[0.09904066,0.004721361,0.8858653,0.000170898,0.004370723,0.000257191,0.003156395,0.0002987945,0.0004217231,0.00001342846,0.001329312,0.0003541956],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910805,0.001166323,0.000006962312,0.001903396,0.0006222795,0.003321914,0.001693612,0.00003449807,0.000170509],"genre_scores_gemma":[0.9964273,0.0002385172,0.00005605941,0.0001351947,0.0006132739,0.001555679,0.00002196631,0.00005317782,0.0008988432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2187162,"threshold_uncertainty_score":0.9999731,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07959678551480229,"score_gpt":0.4405309141356356,"score_spread":0.3609341286208333,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}